These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35981859)

  • 1. Treatment-refractory warts associated with fingolimod.
    Sahi N; Al-Araji SA; Ciccarelli O; Chard DT; Trip SA
    Pract Neurol; 2022 Dec; 22(6):503-504. PubMed ID: 35981859
    [No Abstract]   [Full Text] [Related]  

  • 2. Warts and all: Fingolimod and unusual HPV-associated lesions.
    Triplett J; Kermode AG; Corbett A; Reddel SW
    Mult Scler; 2019 Oct; 25(11):1547-1550. PubMed ID: 30427266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
    Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Müller-Jensen L; Kriedemann H; Anvari K; Huehnchen P; Siffrin V
    Neurology; 2023 Apr; 100(14):670-671. PubMed ID: 36539295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 9. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 10. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 11. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

  • 12. Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
    Baghbanian SM; Amiri MRM
    Neurol Sci; 2021 Mar; 42(3):1175-1177. PubMed ID: 32968870
    [No Abstract]   [Full Text] [Related]  

  • 13. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
    Najdaghi S; Davani DN; Ghajarzadeh M; Shaygannejad V
    Autoimmun Rev; 2022 Dec; 21(12):103203. PubMed ID: 36220524
    [No Abstract]   [Full Text] [Related]  

  • 15. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 17. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

  • 18. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Beadnall HN; Gill AJ; Riminton S; Barnett MH
    Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe fingolimod rebound syndrome after switching to cladribine treatment.
    Coss-Rovirosa F; Salado-Burbano J; Casallas-Vanegas A; Caire-Herrera LE; Gómez-Figueroa E; Flores-Rivera J
    Mult Scler Relat Disord; 2020 May; 40():101938. PubMed ID: 31982666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Walker S; Brew B
    J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.